Cilnidipine and Bradycardia: Clinical Considerations

Pharmacological Profile and Risk of Bradycardia

Dihydropyridine CCBs, such as cilnidipine, are generally not associated with significant bradycardia, unlike non-dihydropyridine CCBs, according to the European Heart Journal 1
Non-dihydropyridine CCBs, like verapamil and diltiazem, are well-documented to cause bradycardia and are contraindicated in patients with pre-existing bradycardia or heart block, as stated by the European Heart Journal and the Journal of the American College of Cardiology 1, 2

Elderly patients may experience greater antihypertensive effects from CCBs due to decreased baroreceptor response and age-related increases in drug exposure, as reported by the European Heart Journal 3
Patients with pre-existing conduction disorders are at higher risk for bradycardia with any medication affecting cardiac conduction, according to Circulation 4
The European Heart Journal recommends monitoring heart rate and blood pressure when initiating cilnidipine, particularly in elderly patients or those with pre-existing conduction disorders 1
Circulation suggests considering alternative antihypertensive agents in patients with pre-existing bradycardia or high-degree AV block 4